Ascidian Therapeutics

United States
Panora, Iowa, United States, 02135

Company profile

Ascidian Therapeutics company profile

Ascidian Therapeutics is redefining the treatment of disease by rewriting RNA. By editing exons at the RNA level, Ascidian therapies enable precise post-transcriptional editing of genes, resulting in full-length, functional proteins at the right levels, in the right cells, at the right time. With active discovery and preclinical programs in ophthalmology, neurological and neuromuscular disorders, and other rare diseases, Ascidian is opening new therapeutic possibilities for patients in need of breakthroughs.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0-$1M
Founded
2020-01-01, Year

Headquarters

Postal code
02135
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
3
Total equity funding
$90M
Last funding
Series A / $40M / 2023-11-08
Last equity funding
Series A / $40M
Investors
1
Lead investors
1
Founders
1
Articles
48

Founders and investors

Founders

Michael Ehlers

Lead investors

Apple Tree Partners

Investors

Apple Tree Partners